Back To Top

Canadian Nuclear Research Initiative: Health (CNRI-H)

Canadian Nuclear Research Initiative: Health (CNRI-H)

Canadian Nuclear Laboratories’ (CNL) Canadian Nuclear Research Initiative-Health Program (CNRI-H) is a program to support collaborative Radiopharmaceutical Discovery, Toxicology and Pre-clinical research, delivered as services of a Contract Research Organization (CRO) on projects with third-party proponents. The goal of the program is to accelerate the discovery, development and approval of targeted radiopharmaceuticals in Canada.

CNRI-H will issue a call for proposals (CFP), and CNL will enter into joint R&D projects based on the results of a review of these proposals. The objective of CNRI-H is to make CNL’s technical capabilities and expert knowledge available and accessible to the Radiopharmaceutical community in order to provide R&D services to them with the technical support required to progress radiopharmaceutical development in Canada.

For more information, or to submit your proposal, email commercial@cnl.ca.

CNRI Program Timeline

October – November: Pre-Launch Feedback Period

November 30, 2021: Call-for-proposals

January 15, 2022: Deadline for proposal submission

April 01, 2022:  Successful agreements announced and work begins

Focus Areas

A call for proposals (CFP) will be issued as part of the CNRI program. Included in each CFP will be a list of focus areas. The list of focus areas is as follows:

Potential Award Details

CNL will enter into a series of jointly funded R&D projects that will utilize S&T services from CNL to accelerate the discovery, development and approval of targeted radiopharmaceuticals in Canada. Projects must be within the CNRI program focus areas. Applicants are expected to, at a minimum, match the value contributed by CNL in monetary or in-kind contribution.

Icon CNL

Get in touch with us to learn more:

Send us your Feedback

Contact our Commercial Services team at commercial@cnl.ca